logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
T

Tadaaki Yamada

Kyoto Prefectural University of Medicine
H指数:41
被引数:6,299

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC

TTF-1表达对PD-L1阴性NSCLC患者接受双重ICI与化疗联合免疫疗法预后分层的预测价值

International Journal of Clinical Oncology
IF2.8
2026-08-040
PRE
Naoya Nishioka; Daiki Murata; Koichi Azuma; Kazuhiro Ito; Takashi Nomizo; Kazuhiko Yamada; Tatsuya Imabayashi; Kentaro Iwanaga; Kenji Chibana; Takayo Ota; Yuuya Nishii; Akira Nakao; Asuka Okada; Kosuke Hamai; Takenori Sakai; Taishi Harada; Keiko Tanimura; Kohei Yoshimine; Yosuke Tamura; Ryuichiro Takaki; Yasuhiro Goto; Makoto Hibino; Tomohiro Oba; Toshiyuki Sumi; Hiroyasu Kaneda; Tadaaki Yamada; Koichi Takayama
Initial biomarker testing strategies and clinical outcomes in advanced non-small cell lung cancer

晚期非小细胞肺癌的初始生物标志物检测策略与临床结局

iScience
IF4.1
2026-05-150
OAAI
Masaki Ishida; Tadaaki Yamada; Yasuhiro Goto; Taiichiro Otsuki; Hirokazu Taniguchi; Taishi Harada; Akihiro Yoshimura; Shinsuke Shiotsu; Asuka Okada; Kazuki Jinno; Hibiki Kanda; Noeru Inoguchi; Mototaka Fukui; Takahiro Yamada; Tae Hata; Hayato Kawachi; Yuki Katayama; Kenji Morimoto; Masahiro Iwasaku; Takashi Kijima
Phase II study of ramucirumab plus erlotinib for treatment-naïve patients with EGFR-mutant non-squamous non-small cell lung cancer and pleural effusion (RELAY-Effusion)

拉姆昔替尼联合厄洛替尼治疗EGFR突变非鳞非小细胞肺癌初治患者伴胸腔积液患者的II期研究（RELAY-Effusion）

Lung Cancer
IF4.4
2026-05-030
OAAI
Hiroyasu Kaneda; Motoko Tachihara; Yukihiro Toi; Shoichi Kuyama; Eiki Ichihara; Yasuhito Fujisaka; Koichi Azuma; Takayasu Kurata; Akihito Kubo; Hisashi Tanaka; Tadaaki Yamada; Toshihide Yokoyama; Takahide Kato; Ken Yamamoto; Nobuyuki Katakami; Ryota Kawai; Hisako Yoshida; Ayumi Shintani; Kenji Sawa; Tomoya Kawaguchi
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria

识别PD-L1高表达非小细胞肺癌中隐藏恶病质亚组：AWGC与Fearon标准的比较分析

journal of cachexia, sarcopenia and muscle
IF0
2026-04-120
OAAI
Naoya Nishioka; Hayato Kawachi; Tadaaki Yamada; Motohiro Tamiya; Yoshiki Negi; Yasuhiro Goto; Akira Nakao; Shinsuke Shiotsu; Keiko Tanimura; Takayuki Takeda; Asuka Okada; Taishi Harada; Koji Date; Yusuke Chihara; Isao Hasegawa; Nobuyo Tamiya; Takeo Ogawa; Masahiro Iwasaku; Shinsaku Tokuda; Takashi Kijima; Koichi Takayama
Gut microbiome-driven modulation of the tumor immune microenvironment optimizes dual checkpoint blockade in advanced non-small-cell lung cancer

肠道微生物组驱动的肿瘤免疫微环境调控优化了晚期非小细胞肺癌的双检查点阻断

ESMO Open
IF8.3
2026-02-160
OAAI
Y. Katayama; A. Fukuda; R. Inoue; H. Kawachi; R. Sawada; T. Harada; A. Yoshimura; A. Okada; S. Shiotsu; Y. Chihara; Y. Takemura; T. Yamada; N. Nishioka; M. Iwasaku; S. Tokuda; T. Takagi; S. Kumagai; S. Koyama; K. Takayama; T. Yamada
Impact of vulnerability on concurrent chemoradiotherapy outcomes in patients with locally advanced non-small cell lung cancer using an integrated clinical trial database

使用整合的临床试验数据库研究脆弱性对局部晚期非小细胞肺癌患者同步放化疗结局的影响

Therapeutic Advances in Medical Oncology
IF4.2
2026-01-170
PRE
Kenji Morimoto; Tadaaki Yamada; Naoya Nishioka; Nobuyuki Yamamoto; Seiji Niho; Isamu Okamoto; Katsuyuki Hotta; Hiroaki Okamoto; Shunichi Sugawara; Toshio Shimokawa; Yuichi Ozawa; Satoshi Oizumi; Koichi Takayama
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy

基于炎症选择最优免疫疗法：用于PD-L1 ≥50%基因突变阴性IV期非小细胞肺癌：帕博利珠单抗单药治疗与联合化疗免疫疗法

TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2025-11-300
PRE
Kunimatsu, Yusuke; Nishioka, Naoya; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Ishida, Masaki; Kijima, Takashi; Takayama, Koichi
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
ANTICANCER RESEARCH
IF1.7
2025-11-011
PRE
Sasada, Aosa; Kawachi, Hayato; Yamada, Tadaaki; Hata, Tae; Goto, Yasuhiro; Amano, Akihiko; Negi, Yoshiki; Watanabe, Satoshi; Furuya, Naoki; Oba, Tomohiro; Ikoma, Tatsuki; Nakao, Akira; Tanimura, Keiko; Taniguchi, Hirokazu; Yoshimura, Akihiro; Fukui, Tomoya; Murata, Daiki; Kaira, Kyoichi; Shiotsu, Shinsuke; Okada, Asuka; Chihara, Yusuke; Kijima, Takashi; Takayama, Koichi
Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study)

开放标签前瞻性II期研究方案：Durvalumab联合卡铂和足叶乙苷治疗晚期大细胞神经内分泌肺癌（LOGIK2401：NECTAR研究）

CANCER TREATMENT AND RESEARCH COMMUNICATIONS
IF0
2025-10-010
OAAI
Ishii, Hidenobu; Azuma, Koichi; Kiyomi, Fumiaki; Yoshimine, Kohei; Uchida, Kazuki; Tobino, Kazunori; Yamada, Tadaaki; Iwasa, Tsutomu; Kanemura, Hiroaki; Sumi, Toshiyuki; Iwama, Eiji; Mori, Masataka; Takenaka, Masaru; Takeyasu, Yuki; Kurata, Takayasu; Misono, Shunsuke; Tanaka, Kentaro; Okamoto, Isamu
Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial

度鲁妥单抗、卡铂和依托泊苷用于治疗初治广泛期小细胞肺癌且体力状况较差的患者（NEJ045A）：一项单臂Ⅱ期试验

The Lancet Respiratory Medicine
IF32.8
2025-09-280
PRE
Tetsuhiko Asao; Yu Saida; Satoshi Watanabe; Akira Kisohara; Kazuma Kishi; Ryo Morita; Taku Nakagawa; Yoko Tsukita; Naoki Furuya; Taichi Miyawaki; Nobuhisa Ishikawa; Tadaaki Yamada; Takahiro Tanaka; Satoshi Morita; Toshiaki Kikuchi; Makoto Maemondo; Kunihiko Kobayashi
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study

免疫检查点抑制剂诱导的间质性肺病（合并与不合并CTLA-4方案）在PD-L1 < 1 %的非小细胞肺癌患者中的研究：一项多中心、回顾性研究

Lung Cancer
IF4.4
2025-09-260
PRE
Daiki Murata; Koichi Azuma; Kenta Murotani; Kazuhiro Ito; Takashi Nomizo; Kazuhiko Yamada; Tatsuya Imabayashi; Kentaro Iwanaga; Kenji Chibana; Takayo Ota; Yuuya Nishii; Akira Nakao; Asuka Okada; Kosuke Hamai; Keiko Tanimura; Kohei Yoshimine; Yosuke Tamura; Ryuichiro Takaki; Yasuhiro Goto; Makoto Hibino; Tomohiro Oba; Toshiyuki Sumi; Hiroyasu Kaneda; Naoya Nishioka; Tadaaki Yamada; Koichi Takayama
Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non–small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102)

阿特珠单抗联合卡铂和nab-紫杉醇组合疗法治疗TTF-1阴性晚期非鳞状非小细胞肺癌：一项多中心、单臂II期试验（F1NE TUNE，LOGiK 2102）

European Journal of Cancer
IF7.1
2025-09-120
PREAI
Yoshimasa Shiraishi; Takayuki Shimose; Motoko Tachihara; Yuko Tsuchiya-Kawano; Ryotaro Morinaga; Hiroyuki Inoue; Yukihiro Toi; Tadaaki Yamada; Masafumi Yamaguchi; Kosuke Kashiwabara; Kazunori Tobino; Hidenobu Ishii; Yoshihiko Sakata; Megumi Inaba; Kazuhisa Nakashima; Kenji Chibana; Tomoya Fukui; Miiru Izumi; Ryota Saito; Hiroshi Ishii; Shota Omori; Shinsuke Ogusu; Kazuto Furuyama; Satoru Miura; Taishi Harada; Isamu Okamoto
Analysis of Poor Prognostic Factors and Treatment Strategies in Platinum-Based Systemic Therapy After EGFR-TKI Failure in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations

携带EGFR突变的患者在EGFR-TKI失败后接受铂类为基础的系统治疗中不良预后因素及治疗策略的分析

Clinical Lung Cancer
IF3.3
2025-07-220
PRE
Tae Hata; Tadaaki Yamada; Naoki Furuya; Hisashi Tanaka; Akihiro Yoshimura; Tomohiro Oba; Makoto Hibino; Takahito Fukuda; Yasuhiro Goto; Akira Nakao; Shinsuke Ogusu; Yuta Okazaki; Taishi Harada; Takayo Ota; Ken Masubuchi; Koji Mikami; Shoki Matsumoto; Ryoichi Honda; Koji Date; Yusuke Chihara
Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study

EGFR突变非小细胞肺癌在EGFR-TKI治疗失败后，化疗免疫疗法批准前后真实世界治疗结局：一项日本队列研究

international journal of oncology
IF2.8
2025-07-220
PRE
Kenji Morimoto; Tadaaki Yamada; Naoki Furuya; Hisashi Tanaka; Akihiro Yoshimura; Tomohiro Oba; Makoto Hibino; Takahito Fukuda; Yasuhiro Goto; Akira Nakao; Shinsuke Ogusu; Yuta Okazaki; Taishi Harada; Takayo Ota; Ken Masubuchi; Koji Mikami; Tae Hata; Shoki Matsumoto; Ryoichi Honda; Koji Date; Yusuke Chihara; Koichi Takayama
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
ONCOIMMUNOLOGY
IF6.3
2024-12-160
OAAI
Kawachi, Hayato; Yamada, Tadaaki; Tamiya, Motohiro; Negi, Yoshiki; Kijima, Takashi; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Morimoto, Kenji; Iwasaku, Masahiro; Tokuda, Shinsaku; Shimose, Takayuki; Takayama, Koichi
EGFR-V834L combined with L858R mutation reduced afatinib sensitivity and associated to early recurrence in lung cancer
TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2024-11-010
OAAI
Terada, Nanao; Koba, Hayato; Nanjo, Shigeki; Kimura, Hideharu; Nishiyama, Akihiro; Yoneda, Taro; Takeda, Takayuki; Shirasaki, Hiroki; Nishi, Koichi; Sone, Takashi; Yamada, Tadaaki; Takayama, Koichi; Shibata, Kazuhiko; Matsuoka, Hiroki; Kita, Toshiyuki; Nagata, Kazuhiro; Tambo, Yuichi; Ohkura, Noriyuki; Hara, Johsuke; Kasahara, Kazuo; Kohsaka, Shinji; Mano, Hiroyuki; Yano, Seiji
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1%to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study

TTF-1表达对PD-L1表达水平为1%至49%的非小细胞肺癌患者预后预测的影响：化疗与化疗免疫治疗的多中心回顾性研究

CANCER RESEARCH AND TREATMENT
IF3.8
2024-10-250
OA
Nishioka, Naoya; Hata, Tae; Yamada, Tadaaki; Goto, Yasuhiro; Amano, Akihiko; Negi, Yoshiki; Watanabe, Satoshi; Furuya, Naoki; Oba, Tomohiro; Ikoma, Tatsuki; Nakao, Akira; Tanimura, Keiko; Taniguchi, Hirokazu; Yoshimura, Akihiro; Fukui, Tomoya; Murata, Daiki; Kaira, Kyoichi; Shiotsu, Shinsuke; Hibino, Makoto; Okada, Asuka; Chihara, Yusuke; Kawachi, Hayato; Kijima, Takashi; Takayama, Koichi
Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort
INVESTIGATIONAL NEW DRUGS
IF2.7
2024-08-210
PRE
Tachibana, Yusuke; Morimoto, Kenji; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Katayama, Yuki; Nishioka, Naoya; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi

研究方向

暂未获取到该数据
K
Koichi Takayama
H 指数:75论文数:954被引数:1.9万
Y
Yusuke Chihara
H 指数:23论文数:157被引数:3,155
K
Kenji Morimoto
H 指数:27论文数:222被引数:4,300
S
Seiji Yano
H 指数:53论文数:562被引数:1.3万
M
Masahiro Iwasaku
H 指数:24论文数:135被引数:1,900
S
Shinsuke Shiotsu
H 指数:17论文数:121被引数:1,396
T
Takayuki Takeda
H 指数:22论文数:196被引数:2,738
J
Junji Uchino
H 指数:32论文数:319被引数:6,839
S
Shinsaku Tokuda
H 指数:19论文数:120被引数:1,581
Y
Yuki Katayama
H 指数:17论文数:88被引数:1,123